Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Farrell

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
CNS Drugs|December 12, 2018
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release FampridineJeremy Hobart, Tjalf Ziemssen, Peter Feys, et al.
Neurorehabilitation and Neural Repair|November 22, 2019
Exploratory Randomized Double-Blind Placebo-Controlled Trial of Botulinum Therapy on Grasp Release After Stroke (PrOMBiS)Amanda Claire Wallace, Penelope Talelli, Lucinda Crook, et al.
Therapeutic Advances in Neurological Disorders|October 12, 2018
Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meetingPhilipp Albrecht, Ingrid Kristine Bjørnå, David Brassat, et al.
Multiple Sclerosis and Related Disorders|November 23, 2024
Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialtyTarunya Arun, Kate Petheram, Emma Tallantyre, et al.
The Journal of International Medical Research|January 31, 2008
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosisRachel Farrell, Klaus Bendtzen, Antonio Bertolotto, et al.
Brain and Behavior|November 27, 2025
The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg TestSean Apap Mangion, Charles Wade, Tom Williams, et al.
Neuromodulation : Journal of the International Neuromodulation Society|December 13, 2019
Reducing Intrathecal Baclofen Related Infections: Service Evaluation and Best Practice GuidelinesMichelle S Balaratnam, Ann Donnelly, Honey Padilla, et al.
Journal of Neurology|November 6, 2021
The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experienceAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
Journal of Neurology|August 8, 2022
The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx studyAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
The Lancet. Neurology|September 22, 2023
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trialAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
CNS Drugs|December 12, 2018
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release FampridineJeremy Hobart, Tjalf Ziemssen, Peter Feys, et al.
Neurorehabilitation and Neural Repair|November 22, 2019
Exploratory Randomized Double-Blind Placebo-Controlled Trial of Botulinum Therapy on Grasp Release After Stroke (PrOMBiS)Amanda Claire Wallace, Penelope Talelli, Lucinda Crook, et al.
Therapeutic Advances in Neurological Disorders|October 12, 2018
Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meetingPhilipp Albrecht, Ingrid Kristine Bjørnå, David Brassat, et al.
Multiple Sclerosis and Related Disorders|November 23, 2024
Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialtyTarunya Arun, Kate Petheram, Emma Tallantyre, et al.
The Journal of International Medical Research|January 31, 2008
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosisRachel Farrell, Klaus Bendtzen, Antonio Bertolotto, et al.
Brain and Behavior|November 27, 2025
The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg TestSean Apap Mangion, Charles Wade, Tom Williams, et al.
Neuromodulation : Journal of the International Neuromodulation Society|December 13, 2019
Reducing Intrathecal Baclofen Related Infections: Service Evaluation and Best Practice GuidelinesMichelle S Balaratnam, Ann Donnelly, Honey Padilla, et al.
Journal of Neurology|November 6, 2021
The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experienceAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
Journal of Neurology|August 8, 2022
The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx studyAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
The Lancet. Neurology|September 22, 2023
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trialAnthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, et al.
Pageof 5